We know from the literature that in diabetes patients with a history of CABG surgery, the addition of an SGLT2 inhibitor to standard treatment reduces the risk of cardiovascular-related mortality and of further hospitalization for heart failure by half. This evidence concerns the gene SLC5A2 and heart failure.